LEVERAGE ARTIFICIAL INTELLIGENCE TO DRIVE INNOVATION IN PHARMA, ENAHNCE PATIENT OUTCOMES, AND ACCELERATE DRUG DISCOVERY AND DEVELOPMENT
Advances in network technologies such as Artificial Intelligence has made headlines for its promise to reduce the cost of drug development and accelerate the speed of drug discovery. The application of Artificial Intelligence has made it possible for life science organizations to analyze large sets of health data to detect and treat diseases early and drive clinical research. As AI systems and platforms continue to emerge, pharma has the opportunity to apply these technological advancements to improve patient outcomes and discover novel drugs.
The inaugural Artificial intelligence and block chain Health Care and Pharma Summit is bringing together senior level executives within healthcare, pharmaceutical, and biotech companies to discuss how to explore how to leverage Artificial intelligence and block chain technologies to improve scientific research and drug discovery.
ADVANCE DRUG DISCOVERY AND DEVELOPMENT: Enable AI-driven discovery systems to optimize clinical and drug development
AI APPLICATIONS AND USE CASES: Explore case study examples of AI application to accelerate innovation and automation
AI DRIVEN INDUSTRY PARTNERSHIPS: Identify the best partners to facilitate internal AI adoption, ensure long term success, and maintain intellectual property
REGULATORY COMPLIANCE: Implement a cutting-edge health data strategy while maintaining compliance with complex privacy and security frameworks
AI BUSINESS INTEGRATION: Consider the organizational change and cultural shift required to scale AI capabilities to overcome bottlenecks in the drug discovery process
AI, BLOCK CHAIN, & FUTURE INNOVATIONS: Discover the future of personalized medicine development, AI, Machine Learning, Cloud- Based platforms and Block Chain technologies in life sciences
Where industry meets AI Innovation
2018 speaking faculty includes:
Former Vice President, Enterprise Intelligence, Catholic Health Initiatives;
Executive in Residence, Business Information and Analytics Advisory Board, Department of Business Information and Analytics, University of Denver